Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Nova MD

FuturHealth
Graded #215

Lower grade

vs+1.3000000000000114
Nova MD
Graded #174

Higher grade

The verdict

Nova MD takes it — 66.9/100 to 65.6/100, but only just.

Nova MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules. FuturHealth is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNova MD +8
60
68
Dose & formulationFuturHealth +17
81
64
Clinical oversightNova MD +15
67
82
Labs & monitoringFuturHealth +7
61
54
FulfillmentNova MD +6
62
68
Contract termsEven
55
55
FuturHealth · left barNova MD · right bar

The numbers

MetricFuturHealthNova MD
WeighScore65.6/10066.9/100
GradeCC
Scorecard rank#215#174
Semaglutide$199/mo (compounded)$175/mo (compounded)
TirzepatideNot disclosed$225/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Nova MD

Graded #174 · C

Strengths

  • On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
  • $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
  • $50 off first tirzepatide order shown publicly
  • Explicit microdose / low-dose program for both semaglutide and tirzepatide
  • Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy not named — only 'accredited facilities'
  • LegitScript certification not confirmed (only 'Licensed US Providers' claims)
  • Per-state availability not listed
  • Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard